Umeclidinium

🧮 Dose calculator

Chronic obstructive pulmonary disease (COPD) · Regimen source: FDA Incruse Ellipta · 2

• • Same time every day; not more than once every 24 h. No adjustment for elderly, renal impairment or moderate hepatic impairment. FDA Incruse Ellipta · 2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Incruse Ellipta · 8.1

  “Risk Summary There are insufficient data on the use of umeclidinium in pregnant women to inform a drug‑associated risk.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Incruse Ellipta · 8.2

  “Risk Summary There is no information available on the presence of umeclidinium in human milk, the effects on the breastfed child, or the effects on milk production.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Incruse Ellipta · 8.4

  “The safety and effectiveness of INCRUSE ELLIPTA have not been established in pediatric patients.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Incruse Ellipta · 8.5

  “No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger subjects.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.